Sign In

Yoram Wijngaarde

Founder And Chief Executive Officer at Dealroom.Co

Founder of dealroom.co, a marketplace for venture capital. The Dealroom database contains over 500,000 startups and tracks their growth in real-time using artificial intelligence. Dealroom is Yoram's first venture. Before that, he was an investment banker at Lehman Brothers and NOAH Advisors.

Highlights

May 11 · twitter

VCs don't really "produce" decacorns but it's interesting data nonetheless

Apr 26 · twitter

𝗚𝗟𝗣-𝟭𝘀 𝗮𝗿𝗲 𝗮 𝗵𝗲𝗹𝗹𝘂𝘃𝗮 𝗱𝗿𝘂𝗴.

Prediction: Eli Lilly could become a multi-trillion company, and Berkshire might pile in.

Eli Lilly closed 2025 at ~$65B in revenue. Guidance for 2026 is $80–83B. Analysts project $95B by 2027 and $107B by 2028.

𝗪𝗵𝘆 𝗟𝗶𝗹𝗹𝘆 𝗶𝘀 𝗽𝘂𝗹𝗹𝗶𝗻𝗴 𝗮𝘄𝗮𝘆 from Novo:

𝗕𝗲𝘁𝘁𝗲𝗿 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗲. Lilly's latest drugs just seem to work a little better, and the pipeline gap is widening.

𝗦𝘂𝗽𝗽𝗹𝘆 𝗰𝗵𝗮𝗶𝗻. Peptides are genuinely hard to make at scale, a highly complex biological process. Lilly invested earlier and harder in capacity. Wegovy spent nearly two years on shortage. Did Novo get high on its own supply?

𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁. Lilly under Dave Ricks has been steady. Novo went through a CEO change, board shakeup and restructuring in 2025.

T𝗵𝗲 𝗯𝗶𝗴𝗴𝗲𝗿 𝗾𝘂𝗲𝘀𝘁𝗶𝗼𝗻: 𝗵𝗼𝘄 𝗯𝗶𝗴 𝗰𝗮𝗻 𝗟𝗶𝗹𝗹𝘆 𝗮𝗰𝘁𝘂𝗮𝗹𝗹𝘆 𝗴𝗲𝘁?

It is already past $1T market cap. Could it become a $3T or $4T company, like Apple?

The analogy is not crazy. Apple sold a $1,000+ device to hundreds of millions of people every few years. A GLP-1 costs around $10,000 per year, is taken chronically, and addresses a population in the hundreds of millions globally.

Only about 1 in 10 Americans are on GLP-1s today. The global obesity population is heading toward 1B people. That is a trillion-dollar market on simple math.

But t𝗵𝗲 𝗱𝘂𝗼𝗽𝗼𝗹𝘆 𝘄𝗶𝗹𝗹 𝗻𝗼𝘁 𝗹𝗮𝘀𝘁 𝗳𝗼𝗿𝗲𝘃𝗲𝗿. Amgen, Roche, Pfizer, AstraZeneca, Hengrui, Innovent and others are all coming. Even Amazon just launched its own GLP-1 program.

Then again, peptides are a whole new modality. Once you have built the science, the manufacturing base, the distribution and patient access at this scale, what else can be built on top?

𝗚𝗟𝗣-𝟭𝘀 𝗮𝗿𝗲 𝗮 𝗵𝗲𝗹𝗹𝘂𝘃𝗮 𝗱𝗿𝘂𝗴.

Prediction: Eli Lilly could become a multi-trillion

Related Questions

What company did Yoram Wijngaarde found?
What does Dealroom.co do?
Where did he work before founding Dealroom?
What is his educational background?
Yoram Wijngaarde
Add to my network

Experience

Director at Noah Advisors Ltd.
Associate at Nomura

Education

Pre - University Degree
Master Of Arts In Economics, Business, University Of Amsterdam